Tumor Necrosis Factor Alfa Antagonists for Pediatric Immune-Mediated Diseases

Marcia L. Buck, Pharm.D., FCCP

Pediatr Pharm. 2007;13(8):1-4. 

In This Article


Over the past decade, the tumor necrosis factor alfa (TNFα) antagonists have had a profound impact on the management of immune-mediated diseases. These agents, infliximab, etanercept, and adalimumab, have been used in the treatment of adults and children with rheumatoid arthritis, Crohn's disease, and a variety of other related conditions.[1,2] They are effective in reducing inflammation and are typically well tolerated. Both infliximab and etanercept have been approved by the Food and Drug Administration (FDA) for use in children, and it is anticipated that adalimumab will also be approved. This issue of Pediatric Pharmacotherapy will review the pharmacology of the TNFα antagonists and recent studies supporting their use in the treatment of children with immune-mediated diseases.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.